SCHEMBL3011978

SCHEMBL3011978

COc1ccc(OC)c(S(=O)(=O)C2CCN(c3nc(Cc4ccccc4OC)cs3)CC2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.44
HPGD P15428 2/20 0.44
L3MBTL1 Q9Y468 3/20 0.43
LMNA P02545 3/20 0.43
HTT P42858 2/20 0.43
USP2 O75604 1/20 0.43
HSD17B10 Q99714 2/20 0.41
KMT2A Q03164 4/20 0.41
GAA P10253 1/20 0.40
MAPT P10636 5/20 0.39
RECQL P46063 2/20 0.39
POLB P06746 1/20 0.39
ADRB2 P07550 1/20 0.39
TSHR P16473 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.38
RAB9A P51151 1/20 0.38
KDM4E B2RXH2 1/20 0.38
THRB P10828 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
MEN1 O00255 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3014447 0.94 ALDH1A1 (0.43) ALDH1A1HPGDL3MBTL1LMNAHTT
SCHEMBL3018728 0.93 ALDH1A1 (0.43) ALDH1A1HPGDL3MBTL1LMNAHTT
SCHEMBL3011434 0.93 MAPT (0.40) ALDH1A1HPGDL3MBTL1LMNAHTT
SCHEMBL3010895 0.93 MAPT (0.42) ALDH1A1HPGDL3MBTL1LMNAHTT
SCHEMBL3018934 0.91 DRD2 (0.40) ALDH1A1HPGDL3MBTL1LMNAHTT
SCHEMBL3015530 0.90 DRD2 (0.40) ALDH1A1HPGDLMNAKMT2AGAA
SCHEMBL3007686 0.90 KMT2A (0.45) ALDH1A1HPGDL3MBTL1LMNAHTT
SCHEMBL2999613 0.90 MAPT (0.44) ALDH1A1HPGDL3MBTL1LMNAHTT
SCHEMBL3002108 0.89 ALDH1A1 (0.39) ALDH1A1HPGDL3MBTL1LMNAHTT
SCHEMBL2997817 0.88 ALDH1A1 (0.47) ALDH1A1HPGDL3MBTL1LMNAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA ALDH1A1 3510/4885HPGD 2894/4885L3MBTL1 1847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.